1147 related articles for article (PubMed ID: 34057079)
1. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
King-Robson J; Wilson H; Politis M;
J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
[TBL] [Abstract][Full Text] [Related]
2. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
3. Entorhinal Tau Predicts Hippocampal Activation and Memory Deficits in Alzheimer's Disease.
Richter N; Bischof GN; Dronse J; Nellessen N; Neumaier B; Langen KJ; Drzezga A; Fink GR; van Eimeren T; Kukolja J; Onur OA
J Alzheimers Dis; 2020; 78(4):1601-1614. PubMed ID: 33164934
[TBL] [Abstract][Full Text] [Related]
4. Association between long-term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using
Li J; Zheng C; Ge Q; Yan S; Paranjpe MD; Hu S; Zhou Y;
J Neurosci Res; 2022 Feb; 100(2):670-680. PubMed ID: 34882830
[TBL] [Abstract][Full Text] [Related]
5. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
[TBL] [Abstract][Full Text] [Related]
6. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
7. Sex modulates the ApoE ε4 effect on brain tau deposition measured by
Liu M; Paranjpe MD; Zhou X; Duy PQ; Goyal MS; Benzinger TLS; Lu J; Wang R; Zhou Y
Theranostics; 2019; 9(17):4959-4970. PubMed ID: 31410194
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
[TBL] [Abstract][Full Text] [Related]
9. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
10. Associations between quantitative [
Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
12. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
14. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
15. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
[TBL] [Abstract][Full Text] [Related]
16. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.
Gomperts SN; Locascio JJ; Makaretz SJ; Schultz A; Caso C; Vasdev N; Sperling R; Growdon JH; Dickerson BC; Johnson K
JAMA Neurol; 2016 Nov; 73(11):1334-1341. PubMed ID: 27654968
[TBL] [Abstract][Full Text] [Related]
17. Tau PET in Alzheimer disease and mild cognitive impairment.
Cho H; Choi JY; Hwang MS; Lee JH; Kim YJ; Lee HM; Lyoo CH; Ryu YH; Lee MS
Neurology; 2016 Jul; 87(4):375-83. PubMed ID: 27358341
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease.
Skouras S; Falcon C; Tucholka A; Rami L; Sanchez-Valle R; Lladó A; Gispert JD; Molinuevo JL
Neuroimage Clin; 2019; 22():101777. PubMed ID: 30913531
[TBL] [Abstract][Full Text] [Related]
20. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
